28 August 2018
Visiongain’s new report Pharmaceutical Contract Manufacturing Market 2017-2027: Active Ingredient (API) and Finished Dose Formulation (FDF), Generic APIs, HPAPIs, Solid Dosages, Injectable Dosages indicates that the pharmaceutical contract manufacturing market will see $88bn in spending in 2021.
The pharmaceutical contract manufacturing market is expected to grow at a CAGR of 6.4% in the first half of the forecast period and CAGR of 5.7% in the second half of the forecast period. The market is estimated at $88bn in 2021 and $124bn in 2027.
The lead analyst of the report said: The contract manufacturing sector is more mature than other sectors of the pharma outsourcing industry and has therefore grown more slowly in recent years. Additionally, external factors such as pharma industry M&A, blockbuster patent expiries and limited funding for pharma development programmes, resulting from the global economic crisis that began in 2008, have restrained growth in the market in the last five years. However, growth continues to be driven by the pharma industry’s need to cut development and manufacturing costs, with a view to improving profitability and allowing companies to focus on core competencies, such as drug discovery and development.
Visiongain forecasts that the pharma contract manufacturing market will grow at mid-high single-digit rate. Growth will be fastest in the contract FDF manufacturing submarket, which will grow with a CAGR of 6.9% between 2014 and 2027. This compares with a CAGR of 5.5% for the contract API manufacturing submarket over the same period. Growth in the contract FDF manufacturing submarket will be driven by demand for injectable manufacturing services, which will in turn be driven by greater development of biological drugs. In the contract API manufacturing submarket, strong demand for generic drugs in both developed and emerging markets will drive growth in the generic API manufacturing subsector”
The 235-page report contains 82 tables and 61 figures that add visual analysis in order to explain the developing trends within the Pharmaceutical Contract Manufacturing Market. Visiongain provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for the leading segments of this market: Active pharmaceutical ingredients (APIs), with sub forecasts for generic APIs, high potency active pharma ingredients (HPAPIs) and other products; Finished dosage formulations (FDFs), with sub forecasts for solid dose forms, injectable dosages and other dosage types; Other applications of outsourced production.
The 235-page report offers market forecasts for the United States (US), Germany, France, the UK, Italy, Spain, Brazil, Russia, India and China, South Korea and Japan.
In addition, the report contains a dedicated leading companies’ chapter covering the leading companies in this field.
The report Pharmaceutical Contract Manufacturing Market 2017-2027: Active Ingredient (API) and Finished Dose Formulation (FDF), Generic APIs, HPAPIs, Solid Dosages, Injectable Dosages report will be of value to anyone who wants to better understand the pharmaceutical contract manufacturing market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the pharmaceutical contract manufacturing industry.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The market for ophthalmic drugs is a growing one.
17 June 2019
Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.
14 June 2019
The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.
06 June 2019
Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.